Validation of plasma metabolites associated with breast cancer risk among Mexican Americans.


Journal

Cancer epidemiology
ISSN: 1877-783X
Titre abrégé: Cancer Epidemiol
Pays: Netherlands
ID NLM: 101508793

Informations de publication

Date de publication:
12 2020
Historique:
received: 06 05 2020
revised: 26 08 2020
accepted: 14 09 2020
pubmed: 4 10 2020
medline: 13 4 2021
entrez: 3 10 2020
Statut: ppublish

Résumé

In our previous breast cancer case control study in Hispanics, we found 14 metabolites whose levels differed between cases and controls. To validate the results, we carried out a nested case control study of 100 incident breast cancer and 100 matched healthy women identified from the Mano-A-Mano Mexican American Cohort study. With the adjustment of parity, education, birth place, language acculturation, BMI category, smoking, drinking, physical activity, and sitting time, 4 metabolites were associated with breast cancer risk: 3-hydroxyoctanoate (Odds ratio (OR) = 1.51, 95% confidence interval (CI): 1.10, 3.47), 3-hydroxybutyrate (BHBA) (OR = 1.42, 95%CI: 1.01, 3.72), linoleate (18:2n6) (OR = 1.39, 95% CI: 1.07, 4.04), and bilirubin (OR = 0.54, 95%CI: 0.42, 0.95). Then, we used 3 non-redundant metabolites, namely 3-hydroxyoctanoate, linoleate (18:2n6), and bilirubin, to generate a metabolic risk score. Increased metabolites risk score was associated with a 1.67-fold increased risk of breast cancer (OR = 1.67, 95%CI: 1.32, 3.94). And the significant association was more evident among those who were diagnosed with cancer earlier during the follow-up (≤ 5 years) than their counterparts. In conclusion, we identified four significant metabolites which may help elucidate metabolic pathways that contribute to breast carcinogenesis. Our findings warrant further replication efforts.

Identifiants

pubmed: 33010726
pii: S1877-7821(20)30160-0
doi: 10.1016/j.canep.2020.101826
pmc: PMC7710579
mid: NIHMS1631132
pii:
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

101826

Subventions

Organisme : NCI NIH HHS
ID : U01 CA179655
Pays : United States

Informations de copyright

Copyright © 2020 Elsevier Ltd. All rights reserved.

Références

Breast Cancer Res Treat. 2011 Apr;126(3):717-27
pubmed: 20872241
Cancer Causes Control. 2001 Dec;12(10):887-94
pubmed: 11808707
Cancer Epidemiol Biomarkers Prev. 2013 Apr;22(4):631-40
pubmed: 23396963
Biochim Biophys Acta. 2013 Oct;1831(10):1533-41
pubmed: 23500888
Metabolomics. 2018 Jul 6;14(7):97
pubmed: 30830410
CA Cancer J Clin. 2018 Nov;68(6):425-445
pubmed: 30285281
Crit Rev Oncol Hematol. 2012 Oct;84(1):1-7
pubmed: 22429650
J Cell Physiol. 2016 Oct;231(10):2128-41
pubmed: 26844415
Clin Cancer Res. 2015 Jan 1;21(1):193-200
pubmed: 25336700
Breast Cancer Res Treat. 2019 Aug;176(3):687-696
pubmed: 30771047
Am J Clin Nutr. 2017 Aug;106(2):637-649
pubmed: 28659298
Biomed Chromatogr. 2016 Jan;30(1):42-7
pubmed: 26179699
Br J Cancer. 2017 Nov 7;117(10):1572-1579
pubmed: 28898231
JAMA. 2011 Feb 16;305(7):691-7
pubmed: 21325185
Int J Mol Med. 2012 Sep;30(3):487-94
pubmed: 22692672
Cancer Res. 2018 Oct 15;78(20):6011-6021
pubmed: 30185547
CA Cancer J Clin. 2018 Jan;68(1):31-54
pubmed: 29160902
J Natl Cancer Inst. 2018 Jun 1;110(6):588-597
pubmed: 29325144
Int J Epidemiol. 2017 Apr 1;46(2):e3
pubmed: 25747868
PLoS One. 2013 May 02;8(5):e63076
pubmed: 23658799
Cell Metab. 2018 Jan 9;27(1):136-150.e5
pubmed: 29249690
Carcinogenesis. 2015 Feb;36(2):243-8
pubmed: 25524924
Nutrients. 2018 May 22;10(5):
pubmed: 29789452
Int J Biochem Cell Biol. 2015 Aug;65:209-21
pubmed: 26073129
Transl Oncol. 2013 Dec 01;6(6):757-65
pubmed: 24466379

Auteurs

Hua Zhao (H)

Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, United States; Department of Family Medicine and Population Health, School of Medicine, Virginia Commonwealth University, Richmond, VA, 23284, United States. Electronic address: hua.zhao@vcuhealth.org.

Jie Shen (J)

Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, United States; Department of Family Medicine and Population Health, School of Medicine, Virginia Commonwealth University, Richmond, VA, 23284, United States.

Yuanqing Ye (Y)

Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, United States; Department of Precision Health and DataScience, School of Public Health, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310058, PR China.

Xifeng Wu (X)

Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, United States; Department of Precision Health and DataScience, School of Public Health, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310058, PR China.

Francisco J Esteva (FJ)

Perlmutter Cancer Center at New York University Langone Health, New York, NY, 10016, United States.

Debasish Tripathy (D)

Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, United States.

Wong-Ho Chow (WH)

Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH